PCAN: September 2020
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Biochemically Relapsed Patients with Prostate Cancer with PSA Levels ≤ 2.0 Ng/ml - Full Text ArticleBackground: The aim of the study was to prospectively evaluate the diagnostic performance of 18F-PSMA-1007 PET/CT in patients with prostate cancer (PCa) after radical treatment and low but rising prostate-specific antigen (PSA) levels.
Methods: We prospectively enrolled 40 consecutive patients after radical treatment (80%—radical prostatectomy, 20%— radiation beam therapy) of PCa and low (0.008 to ≤2.0 ng/ml), rising PSA. Skull to mid-thigh PET/CT imaging was performed 95 (±12) min after injection of 295.5 (±14.1) MBq 18F-PSMA-1007. Detection rate was correlated with PSA levels,